Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329602" target="_blank" >RIV/00064165:_____/16:10329602 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10329602
Result on the web
<a href="http://dx.doi.org/10.1371/journal.pone.0166290" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0166290</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1371/journal.pone.0166290" target="_blank" >10.1371/journal.pone.0166290</a>

Result language
angličtina
Original language name
Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease
Original language description
Background: Serum uric acid (UA) elevation is common in patients with cardiovascular, renal and metabolic diseases. However, no study to date has analysed the role of UA in Fabry disease (FD). Objectives: To evaluate the association between serum UA levels and mortality and morbidity in FD. Materials and Methods: We conducted a post-hoc analysis of a prospectively followed-up cohort of 124 patients with genetically proven FD. Serum UA levels were acquired at baseline; clinical events and mortality were assessed during regular visits every 6 to 12 months. The primary endpoint was a composite of multiple secondary outcomes: all-cause mortality, adverse cardiovascular events, progression of renal dysfunction and stroke or transient ischaemic attack (TIA). Predictive value was assessed using the Cox proportional hazards model and the Kaplan Meyer estimator.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)